Senti Biosciences (SNTI) Enterprise Value (2021 - 2025)
Senti Biosciences' quarterly Enterprise Value came in at -$16.4 million in Q4 2025, up 65.99% year-on-year from -$9.9 million in Q4 2024, and down 34.12% quarter-over-quarter from -$12.2 million in Q3 2025.
Senti Biosciences has reported Enterprise Value for 5 years, with the latest figure at -$16.4 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 65.99% year-over-year to -$16.4 million; the trailing twelve-month figure through Dec 2025 stood at -$16.4 million (up 65.99% YoY), and the FY2025 full-year result was -$16.4 million, up 65.99% from the prior year.
- Enterprise Value for Q4 2025 stood at -$16.4 million, down from -$12.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$10.5 million in Q3 2024, with the low at -$139.8 million in Q2 2022.
- Average Enterprise Value over 5 years is -$52.5 million, with a median of -$39.4 million recorded in 2023.
- Year-over-year, Enterprise Value slumped 99.54% in 2023 and jumped 73.42% in 2024.
- Tracing SNTI's Enterprise Value over 5 years: stood at -$56.0 million in 2021, then tumbled by 75.9% to -$98.6 million in 2022, then soared by 63.58% to -$35.9 million in 2023, then slumped by 34.48% to -$48.3 million in 2024, then surged by 65.99% to -$16.4 million in 2025.
- The last three Enterprise Value figures came in at -$16.4 million (Q4 2025), -$12.2 million (Q3 2025), and -$21.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.42 Mn |
| Sep 30, 2025 | -12.24 Mn |
| Jun 30, 2025 | -21.60 Mn |
| Mar 31, 2025 | -33.80 Mn |
| Dec 31, 2024 | -48.28 Mn |
| Sep 30, 2024 | -10.48 Mn |
| Jun 30, 2024 | -15.90 Mn |
| Mar 31, 2024 | -23.70 Mn |
| Dec 31, 2023 | -35.90 Mn |
| Sep 30, 2023 | -39.43 Mn |
| Jun 30, 2023 | -59.64 Mn |
| Mar 31, 2023 | -76.11 Mn |
| Dec 31, 2022 | -98.56 Mn |
| Sep 30, 2022 | -114.94 Mn |
| Jun 30, 2022 | -139.80 Mn |
| Mar 31, 2022 | -38.14 Mn |
| Dec 31, 2021 | -56.03 Mn |
| Sep 30, 2021 | -73.69 Mn |
| Jun 30, 2021 | -82.94 Mn |